164 related articles for article (PubMed ID: 38048019)
1. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Sheng X; Wang L; He Z; Shi Y; Luo H; Han W; Yao X; Shi B; Liu J; Hu C; Liu Z; Guo H; Yu G; Ji Z; Ying J; Ling Y; Yu S; Hu Y; Guo J; Fang J; Zhou A; Guo J
J Clin Oncol; 2024 Apr; 42(12):1391-1402. PubMed ID: 37988648
[TBL] [Abstract][Full Text] [Related]
5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
6. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
[TBL] [Abstract][Full Text] [Related]
7. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
[No Abstract] [Full Text] [Related]
8. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
9. Disitamab Vedotin: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
[TBL] [Abstract][Full Text] [Related]
10. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
[No Abstract] [Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
McGregor B; O'Donnell PH; Balar A; Petrylak D; Rosenberg J; Yu EY; Quinn DI; Heath EI; Campbell M; Hepp Z; McKay C; Steinberg J; Regnault A; Mazerolle F; Galsky MD
Eur Urol; 2022 May; 81(5):515-522. PubMed ID: 35168844
[TBL] [Abstract][Full Text] [Related]
13. Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.
Jindal T; Chou J; Friedlander T; Barata PC; Koshkin VS
Clin Genitourin Cancer; 2022 Apr; 20(2):189-194. PubMed ID: 34998700
[TBL] [Abstract][Full Text] [Related]
14. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
[TBL] [Abstract][Full Text] [Related]
15. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
16. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M; Nishimura N; Oda Y; Miyamoto T; Ohmori C; Takamatsu N; Itami Y; Tachibana A; Matsumoto Y; Kiba K; Tomioka A; Yamamoto H; Okajima E; Masaomi K; Sakamoto K; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
Jpn J Clin Oncol; 2024 Mar; 54(3):329-338. PubMed ID: 38061911
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
[TBL] [Abstract][Full Text] [Related]
19. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
[TBL] [Abstract][Full Text] [Related]
20. Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE.
Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]